| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 5.1K | 7.4% |
| Total Income | 5.1K | 7.4% |
| Expenditure | 4.6K | 11.3% |
| PBT | 505.00 | 27.0% |
| Net Profit | 389.00 | 31.0% |
| OPM | 10.04% | 3.13pp |
| NPM | 7.58% | 4.23pp |
| EPS | 0.85 | 30.9% |
GE HealthCare Reports Q1 2026: Revenue Up 7.4%, Organic Growth 2.9%
03 May 2026 · 3 May, 6:15 pm
Summary
GE HealthCare reported a 7.4% increase in revenue for Q1 2026, with organic revenue growth of 2.9%. The company's profitability was impacted by a discrete PDx supplier issue, which has since been resolved. Despite this, GE HealthCare is maintaining its topline growth guidance for the full year, driven by strong customer demand globally. However, the company is reducing its profit and free cash flow outlook due to increased inflation assumptions.
Key Highlights
- 1
GE HealthCare reported a revenue increase of 7.4% in the first quarter of 2026, which includes organic revenue growth of 2.9%.
- 2
Total orders increased by 1.1% organically, resulting in a book-to-bill ratio of 1.07 and a backlog of $21.8 billion.
- 3
The net income margin for the quarter was 7.6%, while the adjusted EBIT margin was 13.5%.
- 4
Diluted earnings per share (EPS) stood at $0.85, and adjusted EPS reached $0.99.
- 5
Cash flow from operating activities amounted to $290 million, with free cash flow reaching $112 million.
- 6
The company reaffirms its full-year 2026 topline growth guidance, driven by healthy global end market demand.
- 7
The company reduces its profit and free cash flow outlook for the full year 2026, due to more pronounced inflation assumptions.
Management Comments
Peter Arduini
As we start the year, we’re pleased with topline performance, which came in at the high end of our expectations. Growth was driven by strong commercial execution in Pharmaceutical Diagnostics, including Flyrcado, Advanced Visualization Solutions, and Imaging, as well as services. We are maintaining our topline growth guidance driven by healthy customer demand globally. Profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved. We saw significant increases in memory chips, oil and freight costs during the first quarter that we assume will impact the rest of 2026. Given these dynamics, we are taking a prudent approach and reducing our profit outlook but expect to offset more than half of the inflation impact with price and cost actions. Importantly, we are making meaningful progress executing on our new wave of innovation to accelerate future revenue and margin growth.”
Informational and educational content only. Not investment advice.